Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SETBP1 mutation analysis in 944 patients with MDS and AML.
Thol F, Suchanek KJ, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Kade S, Löffeld P, Banihosseini S, Bug G, Ottmann O, Hofmann WK, Krauter J, Kröger N, Ganser A, Heuser M. Thol F, et al. Among authors: thiede c. Leukemia. 2013 Oct;27(10):2072-5. doi: 10.1038/leu.2013.145. Epub 2013 May 7. Leukemia. 2013. PMID: 23648668 No abstract available.
Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.
Panagiota V, Thol F, Markus B, Fehse B, Alchalby H, Badbaran A, Lehmann U, Koenecke C, Shahswar R, Chaturvedi A, Stadler M, Eder M, Göhring G, Koenigsmann M, Kloos A, Trummer A, Schroeder T, Kobbe G, Thiede C, Platzbecker U, Schlegelberger B, Kreipe HH, Ganser A, Kröger N, Heuser M. Panagiota V, et al. Among authors: thiede c. Leukemia. 2014 Jul;28(7):1552-5. doi: 10.1038/leu.2014.66. Epub 2014 Feb 7. Leukemia. 2014. PMID: 24504025 No abstract available.
Low frequency of calreticulin mutations in MDS patients.
Heuser M, Panagiota V, Koenecke C, Fehse B, Alchalby H, Badbaran A, Shahswar R, Stadler M, Eder M, Göhring G, Trummer A, Schroeder T, Kobbe G, Thiede C, Platzbecker U, Schlegelberger B, Kroeger N, Ganser A, Thol F. Heuser M, et al. Among authors: thiede c. Leukemia. 2014 Sep;28(9):1933-4. doi: 10.1038/leu.2014.165. Epub 2014 May 21. Leukemia. 2014. PMID: 24850292 No abstract available.
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q.
Heuser M, Meggendorfer M, Cruz MM, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F. Heuser M, et al. Among authors: thiede c. Leukemia. 2015 Sep;29(9):1942-5. doi: 10.1038/leu.2015.49. Epub 2015 Feb 24. Leukemia. 2015. PMID: 25792355 No abstract available.
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.
Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, Klut IM, Knoth H, Röllig C, Schetelig J, Mohr B, Graehlert X, Ehninger G, Bornhäuser M, Thiede C. Platzbecker U, et al. Among authors: thiede c. Leukemia. 2012 Mar;26(3):381-9. doi: 10.1038/leu.2011.234. Epub 2011 Sep 2. Leukemia. 2012. PMID: 21886171 Free PMC article. Clinical Trial.
GFI1 as a novel prognostic and therapeutic factor for AML/MDS.
Hönes JM, Botezatu L, Helness A, Vadnais C, Vassen L, Robert F, Hergenhan SM, Thivakaran A, Schütte J, Al-Matary YS, Lams RF, Fraszscak J, Makishima H, Radivoyevitch T, Przychodzen B, da Conceição Castro SV, Görgens A, Giebel B, Klein-Hitpass L, Lennartz K, Heuser M, Thiede C, Ehninger G, Dührsen U, Maciejewski JP, Möröy T, Khandanpour C. Hönes JM, et al. Among authors: thiede c. Leukemia. 2016 Jun;30(6):1237-45. doi: 10.1038/leu.2016.11. Epub 2016 Feb 5. Leukemia. 2016. PMID: 26847026
Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.
Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J. Middeke JM, et al. Among authors: thiede c. Leukemia. 2016 Feb;30(2):261-7. doi: 10.1038/leu.2015.226. Epub 2015 Aug 18. Leukemia. 2016. PMID: 26283567 Clinical Trial.
Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia.
Stölzel F, Platzbecker U, Mohr B, Röllig C, Middeke JM, Thiede C, Füssel M, Hänel M, Schaich M, Ehninger G, Schetelig J, Bornhäuser M. Stölzel F, et al. Among authors: thiede c. Leukemia. 2013 Oct;27(10):2068-72. doi: 10.1038/leu.2013.142. Epub 2013 May 7. Leukemia. 2013. PMID: 23648670 Clinical Trial. No abstract available.
368 results